Rasappa Arumugham

Biography

Dr. Arumugham has a proven track record in drug development, scale-up, and technology transfer, with over 30 years of diverse experience in leading biopharmaceutical research and development in the areas of discovery and pre-clinical research, formulation, analytical development, quality control, and manufacturing. He has supported commercialization of vaccines and biologics including Prevnar®, Prevnar13®, TetramuneTM, Meningitec® and Trumenba®. Dr. Arumugham was the Vice President of Biopharmaceutical Development at Soligenix, Inc where he led development and manufacturing of biologics, peptides and small molecules in support of injectable and topical formulations. He also served as Principal Investigator for the development of a heat-stable ricin vaccine program funded by the US government (NIAID). Dr. Arumugham aslo served as the Head of Microbial Analytics at Merck’s Manufacturing Division. Prior to joining Merck, he spent 25 years in biologics/vaccines research and development, holding positions of increasing responsibilities at Pfizer and Wyeth. Dr. Arumugham earned his PhD and MSc in Biochemistry and BSC in Chemistry from the University of Madras, India. Dr. Arumugham has a proven track record in drug development, scale-up, and technology transfer, with over 30 years of diverse experience in leading biopharmaceutical research and development in the areas of discovery and pre-clinical research, formulation, analytical development, quality control, and manufacturing. He has supported commercialization of vaccines and biologics including Prevnar®, Prevnar13®, TetramuneTM, Meningitec® and Trumenba®. Dr. Arumugham was the Vice President of Biopharmaceutical Development at Soligenix, Inc where he led development and manufacturing of biologics, peptides and small molecules in support of injectable and topical formulations. He also served as Principal Investigator for the development of a heat-stable ricin vaccine program funded by the US government (NIAID). Dr. Arumugham aslo served as the Head of Microbial Analytics at Merck’s Manufacturing Division. Prior to joining Merck, he spent 25 years in biologics/vaccines research and development, holding positions of increasing responsibilities at Pfizer and Wyeth. Dr. Arumugham earned his PhD and MSc in Biochemistry and BSC in Chemistry from the University of Madras, India.

Research Interest

Host defense mechanisms,LPS effects on neurotransmitters